Drug Recall Lawyer Blog

The MDL Panel has agreed with Actos bladder cancers lawyers that all federal Actos claims should be consolidated in an MDL. You can find more information here.

here.

http://www.accidentinjurylawyerblog.com/2012/01/actos_bladder_cancer_lawsuits.html

The FDA has announced today the recall of Vagifresh Ball and Vagifresh Gel. An analysis by the FDA has found that Vagifresh Gel contains benzocaine, an active ingredient for many anesthetic drug products. An analysis of Vagifresh Ball found the product to contain bacteria including Staphylococcus lentus, S. sciuri, Bacillus Lantus, Alloiococcus otitis, Aerococcus viridans, Aeromonas salmonicid, Gemella spp, and Leuconostoc spp.

The FDA has further determined that marketing material for these products contained unsubstantiated therapeutic claims related to various gynecologic conditions that could have caused women taking these products from seeking appropriate medical care for potentially serious medical conditions.

These products, marketed as cosmetics, are applied by inserting deeply into the vagina for a prolonged period of time. Sold in herbal stores, beauty shops, drug stores, the internet, and by mail order. These two products were also sold under the mixed package named Female One, which contained Vagifresh Ball, Vagifresh Gel and Vagifresh Liquid, though this recall does not involve Vagifresh liquid.

Consumers are being instructed to immediately stop using the products and contact their physician if they experienced any problem that may be related to use.

I'm a man. It is not exactly comfortable putting this kind of information out there. But when safety is at issue, you really have to put that kinda stuff aside.

Chantix is mad science messing with the brain

You and Dawson, you both live in the same dreamworld! It doesn't matter what I believe. It only matters what I can prove! So don't tell me what I know, or don't know! I know the LAW!

Lt. Daniel Kaffee, that crazy kid, was on to something here. You can apply Kaffee's logic to Chantix. Chantix is always on the FDA adverse event reports leaderboard, both in terms of breadth and quantity. Where there is smoke, there is usually fire. Not always. But usually.

There is certainly enough of a connection between the smoke in Chantix suicide cases. If someone starts taking Chantix and kills themselves, it will not be difficult to explain to a jury the relationship. It is not a leap to say that if someone has been going through life without killing themselves (obviously), takes Chantix, and then kills themselves, it is going to be more likely than not that Chantix was a contributing cause. Not definitively connected beyond all reasonable doubt - suicide is too complex of an event for that - but certainly more likely that not to be a contributor.

Continue reading "Chantix Lawsuits: What Can Plaintiffs' Lawyer Prove?" »

Last month brought changes to forty (40) medical product labels (down from 48 changes in November), with changes to the prescribing information to include any of the following areas: boxed warnings, contraindications, warnings, precautions, adverse reactions, patient package insert, and medication guide.

For a complete detailed accounting of the label changes, please refer to the summary of meds. By clicking onto the drug name, you will be able to view the detailed summary, which will identify the safety labeling section and revised subsection, as well as a brief summary of the new or modified safety information.

The following medications have been affected:

Multaq (dronedarone hydrochloride) tablets
Dilantin-125 (phenytoin) Oral Suspension
Norvir (ritonavir) Soft Gel Capsules, Oral Solution and Tablets
Relenza (zanamivir) inhalation powder
Tyzeka (telbivudine) tablets and oral solution
Capoten (captopril) Tablets
Danocrine brand of Danazol capsules
Desferal (deferoxamine mesylate) for injection
Edarbi (azilsartan medoxomil) Tablets
Eloxatin (oxaliplatin) for intravenous use
Heparin Sodium Injection
Isentress (raltegravir) scored, chewable tablets, film-coated tablet
Keppra (levetiracetam) Tablets and oral solution
Onglyza (saxagliptin) tablets
Ovide (malathion) 0.5% lotion1
PegIntron (Peginterferon alfa-2b) Injection, Powder for Solution for Subcutaneous Use
Plavix (clopidogrel bisulfate) tablets
Remeron (mirtazapine) tablets and RemeronSolTab (mirtazapine) Orally Disintegrating
Zegerid (omeprazole/sodium bicarbonate) powder for oral suspension and capsules

• November 2011 Medication Label Changes
• October 2011 Medication Label Changes
• September 2011 Medication Label Changes
• August 2011 Medication Label Changes

A recent study has found that there is new evidence that statins could increase women’s risk factor for type 2 diabetes.

Statins, often called wonder drugs, are medicines taken to lower cholesterol levels. Zocor, Lipitor, and Crestor are the most popular of these medications that reduce the risk of heart disease and stroke. Tens of millions of Americans take these medications, but a recent study that followed more than 150,000 women over the age of 50, with and without heart disease, found that those taking statin drugs had a 48 percent greater chance of developing type 2 diabetes. Doctors say that don't know why statins increase diabetes, and that the research does not implicate any single brand. These findings seem to confirm prior smaller studies.

Now, I’m not saying that anyone should panic and stop taking their medication, since heart disease is one of the major complications of diabetes, but the risk is certainly something to consider and, ultimately, discuss with your doctor. Does the benefit outweigh the risk? It is going to depend on the patient.

• Cardiomyopathy and Diabetes: Crestor Lawsuits
• Zocor Warnings Rewritten

The FDA Safety Information and Adverse Event and Reporting Program is advising healthcare professionals and patients of a potential problem with opiate products manufactured and packaged for Endo Pharmaceuticals by Novartis Consumer Health.

Due to problems that occurred when certain products were packaged and labeled at their Lincoln, Nebraska site, tablets from one product may have carried over into packaging of another product, resulting in the possibility of a stray pill of one medicine being placed in the bottle of another product. This is being done as a precuationary measure, as Endo is not aware of any patient having experienced a confirmed product mix-up, nor any adverse events attributable to a product mix-up.

Affected products are as follows:

• Opana ER (oxymorphone hydrochloride) Extended-Release Tablets CII
• Opana (oxymorphone hydrochloride) CII
• Oxymorphone hydrochloride Tablets CII
• PERCOCET (oxycodone hydrochloride and acetaminophen USP) Tablets CII
• PERCODAN (oxycodone hydrochloride and aspirin, USP) Tablets CII
• ENDOCET (oxycodone hydrochloride and acetaminophen USP) Tablets CII
• ENDODAN (oxycodone hydrochloride and aspirin, USP) Tablets CII
• MORPHINE SULFATE Extended-Release Tablets CII
• ZYDONE (hydrocodone bitartrate/acetaminophen tablets, USP) CIII

Novartis Consumer Health, Inc. (NCH) has announced the recall of all lots of select bottle packaging configurations of Excedrin and NoDoz products with expiration dates of December 20, 2014 or earlier, as well as Bufferin and Gas-X Prevention products with expiration dates of December 20, 2013 or earlier.

The recall is being made as a precautionary measure because the products may contain stray tablets, capsules, or caplets from other Novartis products, or contain broken or chipped tablets. These over-the-counter products were distributed nationwide to wholesalers and retailers.

Another Accutane lawsuit in New Jersey ended on Thursday, this time with a hung jury instead of the usual: a big plaintiffs' verdict. The jury had been out for a week; the trial lasted three weeks.

Accutane's manufacturer Hoffman-La Roche said in a press statement that it is "pleased that the jury concluded that [plaintiff] Tanna was unable to prove her case." It said it looks forward to a retrial. I guess if you are wearing rose colored glasses, that is how you would see it. Hoffman-La Roche is taking a beating in these Accutane lawsuits. So maybe a tie is a huge win for them.

As expected, the South Carolina trial judge denied post-trial motions to overturn a $327 million civil penalty against Johnson & Johnson, which was found to have overstated the claims about its antipsychotic drug, Risperdal. The award was $4,000 for each of more than 43,000 letters pushing Risperdal that J&J sendt to doctors, plus $300 each for 509,000 free samples given to doctors that contained detailed package inserts.

Still, J&J made a fortune off of Risperdal, pulling in as much as $3.4 billion a year in sales. Think about that. It is more than a third the size of the NFL and chances are you have never heard of Risperdal. It had ten good years of sales.

The problem, ultimately, is that from an economic standpoint and assuming J&J has no moral compass at all (I don't assume this, by the way), was it still a good play to put Risperdal on the market and push it as they did? Arguably, even after all of the pain (more might come in a lawsuit brought by the country state of Texas), it still probably makes economic sense. That's the problem.

• The Justice Department has recovered $2.2 billion in civil enforcement actions against pharmaceutical companies this year.
• Yes, Tylenol, even at "safe" levels, can hurt you.
• The FDA has warned California Lap-Band practices to stop it with the misleading ads.
• The FDA says it's premature to draw any link between SSRIs during pregnancy and babies with a condition called persistent pulmonary hypertension of the newborn.
• Pfizer has to pay three women who alleged a link between hormone replacement drugs and their breast cancer. HT:TortsProf.

The FDA is advising that an additional concentration of liquid acetaminophen marketed for “infants” is now available. The new concentration, 160 mg/5 ml, will affect the amount of liquid given to an infant, and should be especially noted by consumers who re used to using the 80 mg /0.8 mL or 80 mg/mL concentrations of liquid acetaminophen.

The Over-the-Counter (OTC) Liquid acetaminophen is used to temporarily reduce fever and relieve minor aches and pains due to the common cold, flu, headache, minor sore throat, and toothache.

Acetaminophen is marketed under brand names such as:

• Tylenol
• Little Fevers
• Triaminic
• Infant/Pain Reliever
• Pedia Care
• Triaminic Infants’ Syrup Fever Reducer/Pain Reliever
• store brands (e.g., Rite Aid, CVS, Walgreens brand, etc.)

The FDA is recommending that consumers read the Drug Facts label on the package to identify the concentration of the liquid acetaminophen (in mg/mL), dosage, and directions for use.

• Hydrocodone/Acetaminophen Recall
• Tylenol Linked to Asthma?
• Use of Acetaminophen in Pregnancy Associated With Increased Asthma Symptoms in Children
• Tylenol Liver Damage Symptoms and Information

Johnson & Johnson, eager to pad its record recall year before 2011 closes out, is recalling certain lots of MOTRIN IB, because testing of product samples showed that some caplets may not dissolve as quickly as intended when nearing their expiration date. This is not a consumer level recall, meaning consumers do not need to dispose of or return the product.

There is no safety concern if consumers continue taking the product in accordance with its label; there may just be a delay in experiencing relief. The recall is NOT being made on the basis of any adverse events.

The lot numbers for the recalled product can be found on the side of the carton label. The recalled lots are as follows:

• MOTRIN IB 24 COATED TABLETS - Lot Numbers: ADA069, ALA168, ALA244 AMA286, APA001, ASA001 - UPC Code: 300450463029
• MOTRIN IB 24 COATED CAPLETS - Lot Numbers: ACA310, ACA460, ADA407 AEA262, AFA226, AJA170, ALA037, ALA163, AMA012, AMA331, AMA342, APA035, ASA082, ASA123, ASA285, BDA238, BDA260, BDA383, BEA065, BEA148, BEA269 BEA277, BFA064, BFA144, BFA244, BHA078, BHA147, BHA167, BHA198, BJA164, BJA221, BMA144, BMA215, BMA271, BSA022, BSA056, CBA063, CBA107, CCA028, CDA003, CFA065, CFA100, CHA012, CHA044, CHA066, CHA080, CMA028, CMA035, CMA057, CMA102, CMA108 - UPC Code: 300450481030
• MOTRIN IB 24+6 COATED CAPLETS - Lot Numbers: ACA761, ALA265 - UPC Code: 300450481641

The products were distributed in the United States, Puerto Rico, Bahamas, Fiji, Belize, St. Lucia and Jamaica.

Is this a serious safety hazard for Motrin users? No. But it continues to underscore that Johnson & Johnson needs to get its act together. Drug companies are going to have recalls. Even the best companies are going to have to recall product from time to time. J&J just has way too many.